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mediated 131I-hVEGF siRNA inhibits hepatocellular
carcinoma tumor growth in nude mice
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Background: Hepatocellular carcinoma (HCC) is a primary liver tumor and is the most difficult human malignancy
to treat. In this study, we sought to develop an integrative approach in which real-time tumor monitoring, gene
therapy, and internal radiotherapy can be performed simultaneously. This was achieved through targeting HCC with
superparamagnetic iron oxide nanoparticles (SPIOs) carrying small interfering RNA with radiolabled iodine 131 (131I)
against the human vascular endothelial growth factor (hVEGF).
Methods: hVEGF siRNA was labeled with 131I by the Bolton-Hunter method and conjugated to SilenceMag, a type
of SPIOs. 131I-hVEGF siRNA/SilenceMag was then subcutaneously injected into nude mice with HCC tumors exposed
to an external magnetic field (EMF). The biodistribution and cytotoxicity of 131I-hVEGF siRNA/SilenceMag was assessed
by SPECT (Single-Photon Emission Computed Tomography) and MRI (Magnetic Resonance Imaging) studies and blood
kinetics analysis. The body weight and tumor size of nude mice bearing HCC were measured daily for the 4-week
duration of the experiment.
Results: 131I-hVEGF siRNA/SilenceMag was successfully labeled; with a satisfactory radiochemical purity (>80%) and
biological activity in vitro. External application of an EMF successfully attracted and retained more 131I-hVEGF siRNA/
SilenceMag in HCC tumors as shown by SPECT, MRI and biodistribution studies. The tumors treated with 131I-hVEGF
siRNA/SilenceMag grew nearly 50% slower in the presence of EMF than those without EMF and the control.
Immunohistochemical assay confirmed that the tumor targeted by 131I-hVEGF siRNA/SilenceMag guided by an EMF
had a lower VEGF protein level compared to that without EMF exposure and the control.
Conclusions: EMF-guided 131I-hVEGF siRNA/SilenceMag exhibited an antitumor effect. The synergic therapy of
131I-hVEGF siRNA/SilenceMag might be a promising future treatment option against HCC with the dual functional
properties of tumor therapy and imaging.
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HCC is the fifth most common cancer and the third
leading cause of cancer-related death in the world, with
a particularly high prevalence in Asia and an increasing
incidences in North America, Western Europe and Japan
[1]. Although surgical resection and liver transplant-
ation are potential curative treatments for HCC, their* Correspondence: xwbio2013@gmail.com
5Department of Orthopaedics, Tongji Hospital, Tongji Medical College,
Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
Full list of author information is available at the end of the article
© 2014 Chen et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orapplications are limited by a high incidence of postoper-
ative recurrence and the shortage of grafts. Alternative
strategies such as TACE (TransArterial ChemoEmboliza-
tion) have been applied without showing any improve-
ment in the median survival of patients [2]. Conventional
chemotherapy has been proven insensitive for HCC [3].
To date, no systemic treatments in HCC offered any
significant benefit to patients [4]. Thus, the search for
new therapeutic strategies for HCC is of paramount
importance.
HCC is known as a hypervascularized tumor express-
ing extensive amounts of VEGF, which correlates withtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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major factor contributing to cancer cell survival and
proliferation after irradiation treatment [7-9]. Several
therapeutic approaches have been developed through
inhibiting the binding of VEGF to its receptors, such as
soluble VEGF receptors [10] or anti VEGF antibodies [11].
The disadvantage of these approaches is that they were un-
able to capture or neutralize the VEGF protein that is
already circulating in the system. In this regard, VEGF
siRNA is considered as a better approach for more com-
plete knocking down of VEGF. SiRNA targeted against
VEGF has been shown to silence the VEGF gene, to reduce
the levels of VEGF proteins, and to inhibit tumor growth
in HCC models [12,13]. However, efficient delivery of the
siRNA still remains a challenge. For example, delivery of
VEGF siRNA by adenoviral vectors has off-target effect and
triggers receptor-dependent host tropism. Retroviral vectors
have low titers and liposome vectors show low efficiencies.
To overcome these deficiencies, we conjugated siRNA vec-
tors with SilenceMag and achieved gene delivery by applica-
tion of an EMF. SilenceMag is a type of Superparamagnetic
iron oxide nanoparticles (SPIOs) that are positively charged
thus has good biocompatibility [14]. SPIOs can be easily
combined with negatively charged materials, such as anti-
cancer drugs and nucleic acids, which contribute greatly to
targeted drug delivery and gene transduction [4,15]. SPIOs
have quickly become a popular tool in cancer treatment
and molecular imaging [14].
Multiple molecular imaging modalities have been ap-
plied to track the delivery of siRNAs in vivo. One such
technique is optical imaging technique that presents sev-
eral potential advantages [16,17]. However, a significant
disadvantage is that imaging depth in biological tissue is
limited due to the absorption and scattering of light. 131I
was chosen for this study because its decay emits both γ
rays and β particles. The γ ray was used for imaging and
biodistribution studies in vivo, while the β particle was
used for brachytherapy.
In this study, we employed superparamagnetic iron
oxide nanoparticles (SPIOs) carrying human VEGF siRNA
(hVEGF siRNA) labeled with iodine 131 (131I) and sought
to test its antitumor effect in nude mice.
Methods
Preparation of hVEGF siRNA with 2′-O-methyl modification
We selected siRNA sequences as reported by Yoshifumi
Takei [7]. The hVEGF siRNA (bases 189–207) with the fol-
lowing sense and antisense sequences was used: 5′-GGA
GUACCCUGAUGAGAUCdTdT-3′ (sense), 5′-GAUCUC
AUCAGGGUACUCCdTdT-3′ (antisense). The scrambled
siRNA (SiScr) was used for a control with the following
sense and antisense sequences: 5′-UUCUCCGAACGUG
UCACGUTdTd-3′ (sense), 5′-ACGUGACACGUUCGGA
GAAdTdT-3′ (antisense). Both siRNAs were synthesizedwith a 2′-O-methyl modification of three bases at both 5′
ends by GenePharma Co., and the sense strand of the
hVEGF siRNA was modified with a 5′ amino C6 linker
for radioactive labeling. Additionally, a deoxythymidine
overhang was added to the 3′ end of each single strand
(Figure 1A). All modified siRNAs were produced by
Shanghai GenePharma Co. (Shanghai, China). Chemically
synthesized siRNAs were purified and analyzed with
high-performance liquid chromatogramphy (HPLC). A
high-performance liquid chromatography (HPLC) col-
umn (C18, 5 μm, 4.6 × 250 mm) was purchased from
Agilent Technologies (Santa Clara, CA, USA).Preparation of 131I-hVEGF siRNA/SilenceMag
131I-Na was purchased from Beijing Atom HighTech Co.,
Ltd. (Beijing, China). Bolton-Hunter reagent was pur-
chased from Thermo Scientific Pierce (Rockford, USA).
Bolton-Hunter reagent was labeled with 131I using the
chloramine-T method and then immediately extracted
using a mixture of dimethylformamide (DMF) and benzene
(1:20). A gentle stream of nitrogen dried the organic phase
containing the labeled reagent in a glass vial. To dissolve
the dried, labeled reagent, 10 μl of DMF was added. Next,
5 nmol of hVEGF siRNA in 16 μl of 50 mM borate buffer
(pH 8.5) was added to the DMF solution (Figure 1A). The
mixture was vortexed for a few seconds followed by incu-
bation on ice for 2 h. An excess amount of Bolton-Hunter
reagent (10,000 times the amount of hVEGF siRNA) was
dissolved in 10 μl of DMF and added to the mixture. The
glass vial was then incubated at 4°C overnight. The reac-
tion mixture was purified and concentrated by ultrafil-
tration through a 3,000-molecular weight cutoff filter.
Amicon Ultra-0.5 centrifugal filter devices were purchased
from Millipore Co. (Billerica, USA). The mixture was cen-
trifuged twice at 14,000 × g for 30 min with RNase-free
PBS. The concentrated sample was collected from the de-
vice, and the radiochemical yield of 131I-hVEGF siRNA was
determined.
For preparing 131I-hVEGF siRNA/SilenceMag, 500 ul 10
nM 131I-hVEGF siRNA was mixed with 1 ul ScilenceMag, a
type of SPIOs. which was purchased from OZ bioscience
(France). The complexes were shortly vortexed and allowed
to equilibrate for 30 min at room temperature prior to
analysis. The hVEGF siRNA/SilenceMag and scrambled
siRNA/SilenceMag were synthesized similarly.Radiochemical purity of 131I-hVEGF siRNA/SilenceMag
The radiochemical purity of the 131I-hVEGF siRNA/Silence-
Mag was tested by instant thin-layer chromatography
(ITLC). Silica gel plates and filter paper (No. 1; Hangzhou
Xinhua Paper Manufactory, Hangzhou, China) were used
as the stationary phase. The mobile phase for the silica gel
plate was a mixture of freshly prepared acetone and normal
Figure 1 hVEGF siRNA/SilenceMag and 131I-hVEGF siRNA/SilenceMag knocked down hVEGF in HepG2 cells. A: Scheme showing the
modification of hVEGF siRNA and the Iodination of the hVEGF siRNA using Bolton-Hunter Reagent. B: qRT-PCR analysis of the relative hVEGF
mRNA levels in HepG2 cells, a, blank controls; b, transfected with scrambled siRNA/SilenceMag; c, transfected with hVEGF siRNA/SilenceMag;
d, transfected with 131I-hVEGF siRNA/SilenceMag.
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5% ammonium acetate (1:1) for the filter paper.
Biological activity of 131I- hVEGF siRNA/SilenceMag
HepG2, a human liver cancer cell line, was obtained from
the Cell Bank of Type Culture Collection of Chinese Acad-
emy of Sciences. HepG2 cells were cultured in six-well
plates under 5% CO2 at 37°C in Dulbecco’s modified
Eagle’s medium (DMEM) (Invitrogen, USA). The cells
was treated as follows: group A, blank controls; group B,
transfected with 100 pmol scrambled siRNA/SilenceMag;
group C, transfected with 100 pmol hVEGF siRNA/Silence-
Mag; and group D, transfected with 100 pmol 131I-hVEGF
siRNA/SilenceMag. The cells were incubated with transfec-
tion solution for 6 h and harvested at 24 h. RNA was
isolated using Trizol reagent (Invitrogen). cDNA was syn-
thesized using M-MLV reverse transcriptase 1st-strand
cDNA synthesis kit from Invitrogen (Carlsbad, USA). PCR
was conducted using SYBR Green purchased from Toyobo
Co., Ltd. (Osaka, Japan) and a PCR amplification kit pur-
chased from Takara Biotechnology Co., Ltd. (Shiga, Japan).
Amplification was performed as follows: 95°C for 1 min,
followed by 40 cycles of 95, 58, and 72°C for 15 s each. The
following PCR primer pairs were used for hVEGF and β-
actin, respectively: 5′-CAGCTACTGCCATCCAATCG-3′
and 5′-TTGTTGTGCTGTAGGAAGCTCA-3′, and 5′-G
TCCACCGCAAATGCTTCTA-3′ and 5′-TGCTGTCAC
CTTCACCGTTC-3′. The amount of hVEGF mRNA was
measured relative to the mean critical threshold (CT)
values of β-actin mRNA using the 2-ΔΔCT method.
Animal experiment
6-week-old BALB/C nude male mice were obtained from
Laboratory Animal Centre of Tongji medical college of
Huazhong university of science and technology. The nude
mice were maintained under specific-pathogen-free condi-
tions in the Experimental Animal Centre of Tongji MedicalCollege, Huazhong University of Science and Technology.
This study was performed in strict accordance with the
recommendations in the Guide for the Care and Use of La-
boratory Animals of the National Institutes of Health. The
protocol was approved by the Institute Animal Care and
Use Committee at Tongji Medical College, Huazhong
University of Science and Technology (Permit Number:
IACUC-2010-306). Their care, housing and all manipu-
lations were conducted in accordance with the Guide-
lines for the Care and Use of Experimental Animals
(Animal Care and Use Committee of Tongji Medical
College, Wuhan, China). The animal tumor model was
generated by subcutaneous injection with 0.2 ml of cell
suspension containing 1 × 107 cells into the right flank
of nude mice. When tumor reached an average size of
1.0 cm × 1.0 cm, the mice were randomized into differ-
ent groups and numbered. In addition, all mice were ad-
ministrated 1% potassium iodide in their drinking water
for 1 week before the experiment, in order to reduce
thyroid exposure.
The nude mice bearing human liver cancer were ran-
domized into 4 groups (5 mice per group). The first and
second groups were intravenously injected with 131I-hVEGF
siRNA/SilenceMag, the third with hVEGF siRNA/Silence-
Mag, and the fourth with normal saline as control. An
EMF was bound on the tumor in the nude mice of the first
and third group. Mice in all groups were injected once a
day for 3 days. The weight of mice and the tumor size, in-
cluding length and width, were recorded every day. After
4 weeks, mice were all sacrificed, and their tumors were im-
mediately harvested for immunohistochemical assay. The
curative effect and the toxicity for each treatment strategy
were evaluated with reduction of tumor size and loss of
body weight, respectively.
The dissected tumor tissues were fixed in 4% para-
formaldehyde for 12 h, embedded in paraffin, and seri-
ally sectioned in 4 μm thickness. The tissue was then
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body (Mitaka Biotechnology Co., Ltd) (1:50 dilution,
Santa Cruz Biotechnology, Santa Cruz, USA) overnight at
4°C, and labeled with Streptavidin-Biotin Complex for de-
tection. The slides were counterstained in hematoxylin,
dehydrated through graded ethanol solutions and cover-
slipped.
Blood kinetics of 131I-labeled hVEGF siRNA/SilenceMag
Six nude mice bearing human liver cancer were intra-
venously injected with 131I-hVEGF siRNA/SilenceMag
(3.7 MBq/0.2 ml). Three nude mice were selected at
random. An external magnetic field (EMF) with magnetic
flux density of 0.8 T was positioned at the tumor surface
region on each mouse and remained attached for 12 h.
Approximately 20 ul of blood from tail vein was col-
lected in capillary tubes at 0.5 h、1.0 h、1.5 h、2.0 h、
3.0 h、4.0 h、6.0 h、8.0 h、10.0 h and 12.0 h after tracer
injection. Activity in each blood sample was measured in
a γ-counter, and expressed as a percentage of injected
doses per gram of tissue (% ID/g).
SPECT study and biodistribution of 131I-hVEGF
siRNA/SilenceMag
Six tumor-bearing nude mice, randomly divided into two
groups, were injected intravenously with 18.5 MBq/0.2 ml
131I-hVEGF siRNA. An EMF was bound on the tumor of
each mouse from one group. All the mice were subjected
to SPECT imaging (GE Infinia Hawkeye4) at 30 min after
tracer injection. The mice were then sacrificed for biodis-
tribution study. Tumors and the following tissues were re-
moved and washed: heart, lung, muscle, bone, liver, kidney,
spleen, small intestine, and stomach. Then, the dissected
tissues were assayed in a γ-counter. The results were
expressed as % ID/g.
MRI study
Another six tumor-bearing nude mice were intravenously
injected with 131I-hVEGF siRNA/SilenceMag (18.5 MBq/
0.2 ml). Three nude mice were selected at random, and an
EMF with a magnetic flux density of 0.8 T remained on
tumor surface region for 30 min in each mice. All the
mice underwent a T1WI/T2WI MRI scan (3.0 T MRI sys-
tem, Siemens Magnetom Trio) at 30 min after tracer in-
jection (T1WI: TR/TE 360/13.7 ms, 320 × 320 matrix,
FOV 60 × 60 mm2, 140 Hz/Px of bandwidth, 1.5 mm slice
thickness; T2WI: TR/TE1980/133.9 ms, 320 × 320 matrix,
FOV 60 × 60 mm2, 220 Hz/Px of bandwidth, 1.5 mm slice
thickness). Then, the mice were sacrificed for the biodis-
tribution study with the above-mentioned method.
Statistical analysis
Group data are expressed as the mean ± SD. Nonparamet-
ric Tests were used for data analysis. A P value of ≤0.05indicate statistical significance. Statistical calculations were
performed using SPSS 18.0 for Windows (SPSS, Chicago,
IL, USA).
Results
131I-Labeled hVEGF siRNA/SilenceMag obtained showed
satisfactory radiochemical purity
The 131I-labeled siRNA was successfully prepared using
Bolton-Hunter reagent (Figure 1A). The recovery rate of
hVEGF siRNA was >93.80% after ultrafiltration concen-
tration. The 131I-labeled hVEGF siRNA had a radio-
chemical yield of 18.50 ± 4.80% and a specific activity of
about ~2.20 × 106 Bq/nmol.
The ITLC curves of the concentrated 131I-Labeled
hVEGF siRNA/SilenceMag samples showed a single peak,
demonstrating that the 131I-labeled Bolton-Hunter reagent
and free 131I were effectively removed through ultrafiltra-
tion. Further analysis showed that the radiochemical pur-
ity of the product was >80% (80.46% from the gel plate
chromatography, 84.05% from No. 1 chromatography fil-
ter paper).
HVEGF siRNA/SilenceMag effectively knock down VEGF
expression in HepG2 cells
To test the biological activity of hVEGF siRNA, we in-
cubated HepG2 cells with 131I-hVEGF siRNA/Silence-
Mag in a concentration similar to that in vivo. As
shown in Figure 1B, both hVEGF siRNA/SilenceMag
and 131I-hVEGF siRNA/SilenceMag caused hVEGF
mRNA cleavage effectively in HepG2 cells. hVEGF ex-
pression was more than 5 folds lower compared with
non-transfected (a) and SiScr (b) by qRT-PCR analysis
(Figure 1B). No significant difference in the relative levels
of hVEGF mRNA was observed among cells transfected
with hVEGF siRNA/SilenceMag and 131I-hVEGF siRNA/
SilenceMag (t = 0.21, P = 0.85).
Blood clearance and biodistribution analysis of
131I-labeled hVEGF siRNA/SilenceMag
In order to explore whether 131I- hVEGF siRNA/Silence-
Mag administrated intravenously can reach the tumors and
test its distribution in the tumor-bearing nude mice, we
measured the kinetics of its blood clearance and its bio-
distribution in the nude mice bearing human liver can-
cer. The clearance of 131I-hVEGF siRNA/SilenceMag in
blood followed a monoexponential elimination pattern
and remained in the bloodstream for a short time. The
average biologic half-life (T1/2) was calculated: 2.22 ± 0.17 h
for the mice in the presence of EMF, and 3.37 ±1.17 h for
the other mice in the absence of EMF. No significant
difference between the two groups was found (Z = 1.96,
P = 0.05).
Our result showed that the%ID/g of 131I-hVEGF siRNA/
SilenceMag in tumors with an EMF was more than 2
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P = 0.004). And the % ID/g of 131I-hVEGF siRNA/Silen-
ceMag in all other collected organs did not show signifi-
cant differences with or without an EMF (Figure 2A).
131I-Labeled hVEGF siRNA/SilenceMag accumulated more
in HCC tumor guided by EMF
SPECT study showed that there was increased uptake of
131I-hVEGF siRNA/SilenceMag in the tumors in the
131I-hVEGF siRNA/SilenceMag group in the presence of an
EMF compared with the group without an EMF (Figure 2B).
Mildly increased signal intensity was found on T1WI MRI
on the periphery of tumors in the group of 131I-hVEGF
siRNA/SilenceMag in the presence of EMF compared with
those in the absence of EMF (Figure 2C). However, there
was no significant hypointense on the tumor lesions of both
groups on T2WI MRI (Figure 2C).Figure 2 EMF guidance caused more accumulation and retention of 1
HCC tumor compared with no EMF and control. A: The biodistribution
different organs 30 min after administered to HepG2 xenografts in the pres
SilenceMag scintigraphy taken at 30 min after injection in the HepG2 HCC
C: MRI images of nude mice bearing the HepG2 HCC xenograft 30 min afte
(T1WI): I, in the absence of EMF. II, in the presence of EMF. Lower (T2WI): IIIEMF-guided 131I hVEGF siRNA/SilenceMag inhibited HCC
tumor growth in nude mice without causing significant
weight loss
The tumor growth curves in different groups were shown
in Figure 3A, and the tumor weight and tumor inhibition
rate were listed in Table 1. The final weight of the tumor
in the hVEGF siRNA/SilenceMag group and 131I-hVEGF
siRNA/SilenceMag group with EMF were less than that of
the 131I-hVEGF siRNA/SilenceMag group without EMF
and the control group four weeks after the treatment. The
inhibition rate of 131I-hVEGF siRNA/SilenceMag was
49.80% compared with control while there was no signifi-
cant difference in tumor growth between the hVEGF
siRNA/SilenceMag and the 131I-hVEGF siRNA/Silence-
Mag groups. Immunohistochemical assay showed a dra-
matically decreased expression of VEGF protein in the
tumors of hVEGF siRNA/SilenceMag and 131I-hVEGF31I-hVEGF siRNA/SilenceMag and hVEGF siRNA/SilenceMag in the
of intravenous 131I-hVEGF siRNA/SilenceMag in HCC tumors as well as
ence of EMF (A) or in the absence of EMF (B). B: 131I-hVEGF siRNA/
xenograft. Left: in the presence of EMF. Right: in the absence of EMF.
r intravenously injection of 131I-hVEGF siRNA/SilenceMag. Upper
, in the absence of EMF. IV, in the presence of EMF.
Figure 3 hVEGF siRNA/SilenceMag and 131I-hVEGF siRNA/SilenceMag administration guided by an EMF inhibited HCC tumor growth in
nude mice. A: tumor growth curve after. hVEGF siRNA/SilenceMag and 131I-hVEGF siRNA/SilenceMag xenograft. (1) 131I-hVEGF siRNA/SilenceMag
with EMF; (2) 131I-hVEGF siRNA/SilenceMag without EMF; (3) hVEGF siRNA/SilenceMag with EMF; (4) control group with saline solution. B: VEGF protein
expression by immunohistochemical assay in nude mice bearing HepG2 xenografts 28 days post siRNA administration (magnification × 200). VEGF
protein shows as brownish staining. (a) 131I-hVEGF siRNA/SilenceMag administered intravenously guided by EMF; (b) 131I-hVEGF siRNA/SilenceMag
administered intravenously in the absence of EMF; (c) hVEGF siRNA/SilenceMag administered intravenously guided by EMF; (d) the control group. C:
The weight log of the nude mice bearing the HepG2 HCC xenograft from day 0, injection of hVEGF siRNA/SilenceMag, to day 28. (1) 131I-hVEGF siRNA/
SilenceMag with EMF; (2) 131I-hVEGF siRNA/SilenceMag without EMF; (3) hVEGF siRNA/SilenceMag with EMF; (4) control group.
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of 131I-hVEGF siRNA/SilenceMag without EMF and the
control group showed a higher VEGF protein expression
(Figure 3B).
The weight log of the nude mice bearing the HepG2
HCC xenograft from different groups was shown inTable 1 Tumor inhibition rate of 131I-hVEGF siRNA/
SilenceMag 28 days post treatment








131I-hVEGF siRNA/SilenceMag 978.20±19.90 -6.70±2.20




(Z=1.96, P=0.05)* (Z=0.66, P=0.51)#
Control 916.60±91.20 ―
Z-Value was placed within bracket. *Compared with control. #Compared with
the first group (131I-hVEGF siRNA/SilenceMag + EMF).Figure 3C. There was no significant difference in weight
loss among four groups for the duration of the 4-week
treatment (X2r = 0.93, P = 0.82). This result indicated
that the dosage of 131I-hVEGF siRNA/SilenceMag admin-
istrated in this study did not cause significant cytotoxicity.
Discussion
In the search for a novel and integrative therapeutic
approach in the treatment of HCC, we employed
131I-hVEGF siRNA/SilenceMag, a type of SPIOs that car-
ries hVEGF siRNA and radiolabeled I131. VEGF siRNA is
unstable and has a short half-life. This problem can be
overcome by chemical modification of the synthesized
siRNA. We chose 2′-O-methyl [18,19] for the modification
of our siRNA instead of phosphorothioate [20]. VEGF
siRNA activity decreases as the number of 2′-O-methyl
modified nucleotides increases [21]. We modified three
bases at the 5′ ends of each of the two chains. In this study,
the sense strand of our precursor hVEGF siRNA was modi-
fied with a 5′ amino C6 linker in order to react with
N-hydroxysuccinimide esters of Bolton-Hunter reagent
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hVEGF siRNA was successfully prepared using Bolton-
Hunter reagent. The hVEGF siRNA recovery rate was high.
Its radiochemical yield was 18.5 ± 4.8% and the specific ac-
tivity was about ~2.22 × 106 Bq/nmol. In addition, Silence-
Mag retains its biological activity and can deliver hVEGF
siRNA inside HepG2 cells. During the entire process of the
labeling reaction, SilenceMag did not affect the biological
activity of hVEGF siRNA, which is a prerequisite condition
for gene therapy.
Our biodistribution analysis indicated that 131I-hVEGF
siRNA/SilenceMag stayed in the bloodstream for a
short time. (T1/2: 2.22 ± 0.17 h in the presence of EMF,
3.37 ± 1.17 h in the absence of EMF). 131I-hVEGF siRNA/
SilenceMag can be a tracer in the SPECT study and the
biodistribution study. Both studies showed the increased
uptake of 131I-hVEGF siRNA/SilenceMag in the tumors of
nude mice exposed to EMF. This result confirmed the effi-
cacy of SilenceMag as the carrier of 131I-hVEGF siRNA
under the influence of an EMF in vivo. Additionally, be-
cause of the enhanced permeability and retention effect in
tumor vasculature [23,24], 131I-hVEGF siRNA/SilenceMag
gathering around the tumors was more easily extravasated
in tumor tissues for target gene silencing. We also ob-
served that 131I-hVEGF siRNA/SilenceMag accumulated
slightly more in some normal tissues, such as liver, spleen,
stomach, thyroid, kidneys, bladder etc. The reason may be
as follows: 131I-hVEGF siRNA/SilenceMag cannot evade
the phagocytic uptake by the reticuloendothelial system
of the liver and spleen [25,26]; the end-product of
131I-hVEGF siRNA/SilenceMag metabolism in nude mice
was excreted by the kidneys; 131I-hVEGF siRNA/Silence-
Mag may break down in the body and free 131I could ac-
cumulate in the thyroid and stomach.
We also attempted to use MRI to localize 131I- hVEGF
siRNA/SilenceMag in the tumors. Mildly increased sig-
nal was found on T1WI MRI on the periphery of tumors
in the group of 131I-hVEGF siRNA/SilenceMag with EMF
compared to that without EMF. The T1 relaxation process
requires close proximity of the hydrogen atoms to the
contrast agent [25,27,28], it appears that SilenceMag has a
good hydrophilic nature and is in close proximity to water
molecules, leading to shortening of the spinlattice relax-
ation time and an increased signal intensity. However,
there was no significant hypointense signal on the tumor
lesions on T2WI MRI, which is different from previous re-
ports [27]. This could be due to the different characteris-
tics of SPIOs and the limited amount of SilenceMag in the
local tumor microenvironment. The T2 relaxation occurs
because of the exchange of energy between protons in
water molecules [25,27,28]. In the presence of EMF, SPIOs
create inhomogeneity in the magnetic field of the micro-
environment which leads to dephasing of the magnetic
moments of protons and hence caused T2 shortening. Inthis study, the amount of 131I-hVEGF siRNA/SilenceMag
might be too limited to shorten T2 thus appear hypoin-
tense. Therefore, we concluded that 131I-hVEGF siRNA/
SilenceMag is less sensitive in MRI study than in SPECT
imaging.
We successfully validated the antitumor efficacy of
hVEGF siRNA/SilenceMag in xenograft nude mice using
intravenous injection. The tumor-bearing nude mice re-
ceiving 131I-hVEGF siRNA/SilenceMag and hVEGF siRNA/
SilenceMag with EMF showed a considerable reduction of
tumor growth compared to those receiving 131I-hVEGF
siRNA/SilenceMag without EMF and the controls. How-
ever, there was no significant difference in tumor growth
between the 131I-hVEGF siRNA/SilenceMag group and the
hVEGF siRNA/SilenceMag group in the present of EMF.
This may be caused by the limited dosage of 131I radiation
in the local tumors. The results from immunohistochemi-
cal assay demonstrated a strong inhibitory effect of VEGF
siRNA on VEGF expression in the tumors of the groups
receiving 131I-hVEGF siRNA/SilenceMag and hVEGF
siRNA/SilenceMag with EMF. Finally, there was no signifi-
cant difference in weight loss among the four groups for
the 4-week duration of the siRNA treatment, which sug-
gests that 131I-hVEGF siRNA/SilenceMag t has a tolerable
cytotoxicity.
Our study here suggests that SilenceMag mediated
131I-hVEGF siRNA guided by EMF for HCC targeted
therapy has potential prospective. However, a few prob-
lems need to be addressed in future research: (1) the prep-
aration of 131I-hVEGF siRNA was simple in this study, but
it had a relatively low radiochemical yield (18.5 ± 4.8%),
which went against synergic hVEGF siRNA gene therapy
and 131I brachytherapy; (2) 131I-hVEGF siRNA/SilenceMag
need to be guided by a magnetic field for targeting
tumors, which limit its application; (3) the accumulation
of 131I-hVEGF siRNA/SilenceMag in non-targeted tissues
may induce adverse effects in vivo. Future studies
will focus on the improvement of the labeling method of
131I-hVEGF siRNA and suitable surface modification on
SilenceMag to improve its stability and increase its
targeted function in vivo.Conclusions
Radioiodine labeling of hVEGF siRNA by the Bolton-
Hunter method is simple and reliable, although its radio-
chemical yield needs further improvement. SilenceMag
can successfully deliver hVEGF siRNA into the tumors,
guided by an EMF, with angiostatic and antitumoral ef-
fects via VEGF knock-down. The dual functional proper-
ties of 131I-hVEGF siRNA/SilenceMag in tumor therapy
and imaging provide an attractive system where real time
monitoring of gene delivery, gene therapy and radionuclide
brachytherapy can be integrated. Therefore, the synergy
Chen et al. BMC Cancer 2014, 14:114 Page 8 of 8
http://www.biomedcentral.com/1471-2407/14/114therapy of 131I-hVEGF siRNA/SilenceMag might be a fu-
ture treatment option against HCC.
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